Applications of 2,3-Dibromo-6-Picoline in Industrial Manufacturing

As the original manufacturer of 2,3-Dibromo-6-picoline, we cater to specialized industrial sectors with rigorously controlled quality standards. Below, we present major downstream application scenarios, focusing on end-use industries where this raw material plays a critical role in synthesis, supported by regulatory compliance and practical formulation data.

1. Agrochemical Intermediate for Pyridine-Based Herbicides

Major global crop protection formulators utilize this compound as a strategic halogenated building block in the synthesis of specific pyridine-derived herbicides. The bromo substituents enhance reactivity during subsequent N-alkylation or coupling steps, critical for constructing advanced molecular frameworks of selective weed control agents. Its introduction ensures controlled substitution within multi-step synthetic routes, aligning with target molecule design and minimizing process impurities.

Industry compliance standards

• OECD Guidelines for Testing of Chemicals
• REACH Regulation (EC) No 1907/2006
• US EPA Pesticide Registration (FIFRA)
• ISO 9001:2015 certified QC procedures

Typical usage ratio

• Across herbicide active ingredient synthesis, typically 0.1–0.5 molar equivalents per target intermediate; precise proportion determined by batch process yield and impurity control strategy.

Downstream process integration

• Charged during initial halogenation or heterocycle modification stages in multi-stage synthesis; ensures desired substitution pattern for subsequent condensation or alkylation.

Final product types

• Pyridine-based herbicide technical concentrates
• Water-dispersible granules (WDG)
• Suspension concentrates (SC)
• Ready-to-use herbicide formulations

2. Pharmaceutical Intermediate for Antiviral Active Substances

The pharmaceutical sector incorporates this specialized intermediate in the synthesis of halogenated heterocyclic building blocks, vital for producing advanced intermediates used in antiviral drug development. Our material’s purity facilitates high conversion yields during N-oxidation or Suzuki coupling stages. Medicinal process chemists leverage its unique reactivity profile to design efficient, scalable reaction steps for regulatory submission and clinical material generation.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (current version)
• US FDA cGMP 21 CFR Parts 210 & 211
• China Pharmacopoeia (ChP)

Typical usage ratio

• Generally 1.0–1.2 molar equivalents per step, with ratio set by downstream yield targets and side product minimization for primary antiviral scaffolds.

Downstream process integration

• Directly introduced during early-stage halogenated intermediate synthesis, preceding coupling or cyclization steps necessary for key antiviral compound scaffolds.

Final product types

• GMP-grade pharmaceutical intermediates
• Halogenated heterocyclic drug substances (R&D and clinical trial stage)
• NCE (new chemical entity) building blocks

3. Fine Chemical Building Block for Specialty Pigments

Advanced pigment manufacturers rely on this compound as a halogen source to construct novel pyridine-based chromophores and dye precursors. The electron-withdrawing bromine atoms alter chromophore conjugation, enabling precise color tuning and thermal stability. Our consistent quality supports fine-tuning pigment performance, critical for applications in industrial coatings and high-end plastics.

Industry compliance standards

• EU REACH SVHC List Compliance
• ISO 9001:2015 Quality Management
• EN 71-3:2019 (Toy Safety - migration of certain elements, for downstream pigment use)

Typical usage ratio

• Used at 2–8% (w/w) of total starting material mass for pyridine pigment precursor synthesis; ratio optimized according to targeted hue and chroma properties.

Downstream process integration

• Incorporated during early bromination or ring functionalization within pigment chromophore synthesis, prior to subsequent dye-fixing or finishing reactions.

Final product types

• Pyridine-derived pigments
• Specialty disperse dyes for plastics
• Heat-resistant industrial colorants

4. Key Intermediate for Custom Electronic Material Precursors

The electronics chemical industry uses this compound to build tailored nitrogen-containing aromatic rings for semiconducting and conductor precursor compounds. Its high reactivity supports the construction of stable poly-heterocyclic frameworks needed for high-voltage insulators and certain photoresist monomers, where residue minimization and precise halogen placement influence end-device reliability.

Industry compliance standards

• IEC 62474: Material Declaration for Products of and for the Electrotechnical Industry
• RoHS 2011/65/EU Restriction of Hazardous Substances
• UL 94 Flammability Standard (for end-use device certification, pigment precursor evaluation)

Typical usage ratio

• Often at 5–10 mol% in precursor formulations, depending on required molecular architecture and downstream device performance targets.

Downstream process integration

• Fed into N-alkylation and electrophilic substitution reactions during upstream preparation of polyaromatic intermediates and subsequent material purification stages.

Final product types

• Specialty electronic-grade resin intermediates
• Photoresist precursors
• Functional electronic coating additives

5. Intermediate for Veterinary Drug Synthesis

Developers of veterinary pharmaceuticals deploy this compound as a high-purity intermediate for constructing halogenated pyridine rings integrated into anti-parasitic and anti-infective agents. Its structural properties streamline multi-step synthesis, permitting predictable reactivity and isolation of desired intermediates prior to final bioactive formation. Regulatory-driven batch records demand strict input control, traceable to upstream raw material verification.

Industry compliance standards

• VICH GL3 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients for Veterinary Use
• US FDA CVM Guidelines
• European Pharmacopoeia, Veterinary Section

Typical usage ratio

• Ranges from 0.2 to 0.6 molar equivalents per step, dependent on desired substitution level and impurity rejection thresholds in final veterinary ingredient profile.

Downstream process integration

• Charged during initial heterocycle functionalization, upstream of hydrogenation or thiolation sequences in veterinary medicinal chemistry pipelines.

Final product types

• Veterinary pharmaceutical intermediates
• Halogenated anti-parasitic drug scaffolds
• Active veterinary drug ingredients (API) for oral and topical applications